Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Ultragenyx Pharmaceutical, maintaining a price target of $116.
September 16, 2024 | 4:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Ultragenyx Pharmaceutical, maintaining a price target of $116. This suggests confidence in the company's potential for growth.
The reiteration of an Overweight rating and a maintained price target of $116 by Cantor Fitzgerald indicates a positive outlook on Ultragenyx Pharmaceutical's stock. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100